Credo Life Science
Posted on 27th January 2022

Posted on 27th January 2022

Tamsulosin HCl is an alpha-1 adrenergic receptor blocker widely prescribed for the symptomatic treatment of benign prostatic hyperplasia (BPH). With global prevalence of BPH increasing alongside an ageing population, the demand for a reliable Tamsulosin Manufacturer has never been higher.
Tamsulosin's side-effect profile — particularly postural hypotension — is significantly reduced when the drug is delivered as a controlled-release formulation. This makes Tamsulosin HCl Prolonged-Release Pellets (0.4 mg) the standard of care globally. The complexity of manufacturing these pellets demands a manufacturer with proven expertise in modified-release drug delivery.
Credo Life Sciences manufactures Tamsulosin HCl Extended-Release Pellets in our advanced pellet manufacturing unit. Our fluid bed processors enable precise membrane coating with ethylcellulose-based systems, delivering reproducible drug release profiles. Each batch undergoes multi-point dissolution testing, content uniformity assessment, and comprehensive physical characterisation.
As a preferred Tamsulosin Manufacturer, Credo Life Sciences delivers the technical precision, regulatory documentation, and supply reliability that global pharma companies demand. Connect with our business development team to begin the conversation.